Equities

Bioxytran Inc

BIXT:QBB

Bioxytran Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.10
  • Today's Change0.002 / 2.28%
  • Shares traded5.38k
  • 1 Year change-47.92%
  • Beta-0.7359
Data delayed at least 15 minutes, as of Oct 08 2024 20:56 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

  • Revenue in USD (TTM)0.00
  • Net income in USD-3.51m
  • Incorporated2008
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AIM ImmunoTech Inc201.00k-28.05m16.59m26.00--2.45--82.54-0.5703-0.57030.0040.10680.0082--12.187,730.77-113.70-45.64-149.16-48.3571.14-231.75-13,952.74-11,695.01----0.3018--43.26-11.26-48.94--35.73--
Microbot Medical Inc0.00-10.44m16.83m22.00--2.69-----0.81-0.810.000.37930.00----0.00-113.94-53.28-133.34-62.65------------0.00------18.44---31.76--
Geovax Labs Inc300.68k-26.92m16.88m17.00------56.14-13.05-13.050.1389-0.55260.0237----17,687.06-212.40-108.34-362.39-147.24-----8,951.51-1,842.93---------100.00---85.20------
Biomx Inc0.00-26.25m17.00m58.00---------0.4575-0.45750.000.39290.00----0.00-47.79---57.76--------------0.00------7.59------
Palatin Technologies, Inc.4.49m-29.74m17.02m30.00------3.79-1.97-1.970.2981-0.00620.31310.37133.08149,669.70-207.35-55.28-1,527.99-69.0897.83---662.26-1,359.141.01-------7.49-40.52-23.71--3.31--
Impact Biomedical Inc0.00-4.25m17.25m1.00--0.7399-----0.3694-0.36940.002.030.00----0.00-9.59---15.04-------------5.120.3377---100.00--38.51------
Synlogic Inc3.17m-56.16m17.54m6.00--1.10--5.53-7.24-7.240.35491.370.0628----528,333.30-111.31-40.57-131.17-43.82-----1,771.74-3,245.93----0.00--185.685.9913.40---48.05--
Bioxytran Inc0.00-3.51m17.80m2.00---------0.023-0.0230.00-0.00230.00-------2,635.88-1,420.53---------------20.68---------73.71------
MEI Pharma Inc65.30m17.78m18.06m28.001.020.54680.99420.27652.672.679.804.960.8052--1,536.402,332,036.0021.92-21.0926.64-23.99----27.23-72.23----0.00--33.7667.75155.84---49.68--
Cocrystal Pharma Inc0.00-17.93m18.11m12.00--1.04-----1.76-1.760.001.710.00----0.00-61.98-50.94-66.88-52.77-------1,501.78----0.00------53.69--33.34--
Sol Gel Technologies Ltd6.56m-14.92m18.14m36.00--0.5198--2.77-0.5354-0.53540.23551.250.1351--1.59182,194.40-30.72-31.60-34.59-35.49-----227.40-135.76----0.00---59.9864.50-82.52---33.78--
Minerva Neurosciences Inc0.00-33.65m18.18m9.00---------4.44-4.440.00-6.360.00----0.00-59.32-49.89-62.70-52.39-------442.65------------6.55------
Finch Therapeutics Group Inc0.00-14.17m18.47m18.00--1.30-----8.82-8.820.008.860.00-------25.20---28.80--------------0.00---87.57--34.80------
Spruce Biosciences Inc9.57m-43.11m18.59m22.00--0.3141--1.94-1.05-1.050.23381.430.095----330,069.00-42.79-41.24-52.43-46.49-----450.38-1,774.39---117.260.0412-------3.77------
Monopar Therapeutics Inc0.00-7.12m18.80m10.00--3.09-----2.31-2.310.001.730.00----0.00-81.33-54.07-102.31-60.60------------0.00------20.10------
Kairos Pharma Ltd0.00-2.01m19.01m-----------0.1562-0.15620.00-0.20670.00-------199.80-----------------15.58---------72.57------
Data as of Oct 08 2024. Currency figures normalised to Bioxytran Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.